Torrent Pharmaceuticals outperformer, target Rs 455: Karvy

Published on Fri, Nov 06, 2009 at 17:37 |  Source : Moneycontrol.com

Updated at Fri, Nov 06, 2009 at 17:51  

6243 Investors following Torrent Pharma. Share this News with them.
0
0
Share on Tumblr
Torrent Pharmaceuticals outperformer, target Rs 455: Karvy

ALSO READ

Karvy Stock Broking has recommended an outperformer rating on Torrent Pharmaceuticals , with price target of Rs 445, in its report dated November 6, 2009.

"We marginally downgrade our revenues by 1.4 % in FY 2010 to Rs 18,628 mn and by 2.1% to Rs 21,447 mn in FY 2011 on account of growth concerns of the company's Heumann business in the German market. However, we upgrade our FY 2010E EPS by 6.6 % to Rs.30.7 and FY2011E EPS by 7.2% to Rs 35.7 due to higher operating margins clocked by the company during 1HFY10 owing to better product mix. The stock is currently quoting at 12.4x FY 2010E and 10.6x FY 2011E.We upgrade our price target by 34.8% to Rs.445 based on 12.5x FY11E EPS. We maintain Outperformer rating on the stock." says Karvy.


Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment.........

Attachments : Daily 06-11-09.pdf

  

More on Moneycontrol

Trending News

Business News

HC continues with criminal proceedings against Yahoo! India
Rupee rally may stall with fall against US dollar, euro "Rupee rally may stall with fall against US dollar, euro"

CNBC-TV18 ALERT PM Meets Key Cabinet Ministers On The 2G Case

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 10 2012, 21:39

Tulsian buys steel stocks; negative on sugar, ADAG

- in MARKET OUTLOOK

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 10 2012, 15:43 | Source: CNBC-TV18

Growth in margins sustainable going forward: Shasun Pharma  

Feb 10 2012, 15:35 | Source: CNBC-TV18

Expect Q4 GRMs to be similar to Q3: BPCL  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com